Production (Stage)
Kymera Therapeutics, Inc.
KYMR
$47.62
-$0.04-0.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 198.89% | 97.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 198.89% | 97.65% | |||
| Cost of Revenue | 11.75% | 18.88% | |||
| Gross Profit | 9.73% | -13.68% | |||
| SG&A Expenses | -0.37% | 5.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.50% | 16.19% | |||
| Operating Income | 7.84% | -11.97% | |||
| Income Before Tax | 7.31% | -13.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.31% | -13.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.31% | -13.23% | |||
| EBIT | 7.84% | -11.97% | |||
| EBITDA | 9.72% | -14.30% | |||
| EPS Basic | 7.48% | -7.76% | |||
| Normalized Basic EPS | 7.49% | -7.76% | |||
| EPS Diluted | 7.48% | -7.76% | |||
| Normalized Diluted EPS | 7.49% | -7.76% | |||
| Average Basic Shares Outstanding | 0.20% | 5.07% | |||
| Average Diluted Shares Outstanding | 0.20% | 5.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||